Literature DB >> 25380982

Synthesis and evaluation of anticancer activity in cells of novel stoichiometric pegylated fullerene-doxorubicin conjugates.

George E Magoulas1, Marina Bantzi, Danai Messari, Efstathia Voulgari, Chrisostomi Gialeli, Despoina Barbouri, Athanassios Giannis, Nikos K Karamanos, Dionissios Papaioannou, Konstantinos Avgoustakis.   

Abstract

PURPOSE: To synthesize pegylated stoichiometrically and structurally well-defined conjugates of fullerene (C60) with doxorubicin (DOX) and investigate their antiproliferative effect against cancer cell lines.
METHODS: Stoichiometric (1:1 and 1:2) pegylated conjugates of C60 with DOX were synthesized using the Prato reaction to create fulleropyrrolidines equipped with a carboxyl function for anchoring a polyethylene glycol (PEG) moiety and either a hydroxyl group for attaching one molecule of DOX or a terminal alkyne group for attaching two molecules of DOX through a click reaction. In both conjugates, the DOX moieties are held through a urethane-type bond. Drug release was studied in phosphate buffer (PBS, pH 7.4) and MCF-7 cancer cells lysate. The uptake of the conjugates by MCF-7 cancer cells and their intracellular localization were studied with fluorescence microscopy. The antiproliferative activity of the conjugates was investigated using the WST-1 test.
RESULTS: One or two DOX molecules were anchored on pegylated C60 particles to form DOX-C60-PEG conjugates. Drug liberation from the conjugates was significantly accelerated in the presence of tumor cell lysate compared to PBS. The conjugates could be internalized by MCF-7 cells. DOX from the conjugates exhibited much delayed, compared to free DOX, localization in the nucleus and antiproliferative activity.
CONCLUSION: Pegylated DOX-C60 conjugates (1:1) and (2:1) with well-defined structure were successfully synthesized and found to exhibit comparable, but with a delayed onset, antiproliferative activity with free DOX against MCF-7 cancer cells. The results obtained justify further investigation of the potential of these conjugates as anticancer nanomedicines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25380982     DOI: 10.1007/s11095-014-1566-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

1.  Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance.

Authors:  Andrew Burgess; Suzanne Vigneron; Estelle Brioudes; Jean-Claude Labbé; Thierry Lorca; Anna Castro
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-10       Impact factor: 11.205

2.  Buckysomes: fullerene-based nanocarriers for hydrophobic molecule delivery.

Authors:  Ranga Partha; Linsey R Mitchell; Jennifer L Lyon; Pratixa P Joshi; Jodie L Conyers
Journal:  ACS Nano       Date:  2008-09-23       Impact factor: 15.881

Review 3.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.

Authors:  H Maeda; J Wu; T Sawa; Y Matsumura; K Hori
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

4.  Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis.

Authors:  Olivier Gavet; Jonathon Pines
Journal:  Dev Cell       Date:  2010-04-20       Impact factor: 12.270

5.  Cellular localisation of a water-soluble fullerene derivative.

Authors:  Sarah Foley; Colin Crowley; Monique Smaihi; Claude Bonfils; Bernard F Erlanger; Patrick Seta; Christian Larroque
Journal:  Biochem Biophys Res Commun       Date:  2002-05-31       Impact factor: 3.575

6.  Fullerenol-cytotoxic conjugates for cancer chemotherapy.

Authors:  Padmaparna Chaudhuri; Abhimanyu Paraskar; Shivani Soni; Raghunath A Mashelkar; Shiladitya Sengupta
Journal:  ACS Nano       Date:  2009-09-22       Impact factor: 15.881

Review 7.  Toxicity of pristine versus functionalized fullerenes: mechanisms of cell damage and the role of oxidative stress.

Authors:  Andreja Trpkovic; Biljana Todorovic-Markovic; Vladimir Trajkovic
Journal:  Arch Toxicol       Date:  2012-05-05       Impact factor: 5.153

Review 8.  Functionalized fullerenes in water. The first 10 years of their chemistry, biology, and nanoscience.

Authors:  Eiichi Nakamura; Hiroyuki Isobe
Journal:  Acc Chem Res       Date:  2003-11       Impact factor: 22.384

9.  Aqueous Compatible Fullerene-Doxorubicin Conjugates.

Authors:  Fushen Lu; Sk Anwarul Haque; Sheng-Tao Yang; Pengju G Luo; Lingrong Gu; Alex Kitaygorodskiy; Huaping Li; Sebastian Lacher; Ya-Ping Sun
Journal:  J Phys Chem C Nanomater Interfaces       Date:  2009-10-15       Impact factor: 4.126

10.  Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 and Cdc25 are inhibited.

Authors:  Tamara A Potapova; Sushama Sivakumar; Jennifer N Flynn; Rong Li; Gary J Gorbsky
Journal:  Mol Biol Cell       Date:  2011-02-16       Impact factor: 4.138

View more
  4 in total

1.  Fullerenes in Biology and Medicine.

Authors:  Edison Castro; Andrea Hernandez Garcia; Gerardo Zavala; Luis Echegoyen
Journal:  J Mater Chem B       Date:  2017-07-08       Impact factor: 6.331

2.  Study of the cytotoxic effects of the new synthetic Isothiocyanate CM9 and its fullerene derivative on human T-leukemia cells.

Authors:  Elena De Gianni; Eleonora Turrini; Andrea Milelli; Francesca Maffei; Marco Carini; Anna Minarini; Vincenzo Tumiatti; Tatiana Da Ros; Maurizio Prato; Carmela Fimognari
Journal:  Toxins (Basel)       Date:  2015-02-11       Impact factor: 4.546

3.  C60 fullerene and its nanocomplexes with anticancer drugs modulate circulating phagocyte functions and dramatically increase ROS generation in transformed monocytes.

Authors:  Larysa M Skivka; Svitlana V Prylutska; Mariia P Rudyk; Nataliia M Khranovska; Ievgeniia V Opeida; Vasyl V Hurmach; Yuriy I Prylutskyy; Leonid F Sukhodub; Uwe Ritter
Journal:  Cancer Nanotechnol       Date:  2018-10-31

Review 4.  Antitumor Activity and Potential Mechanism of Novel Fullerene Derivative Nanoparticles.

Authors:  Lianjie Ye; Larwubah Kollie; Xing Liu; Wei Guo; Xiangxian Ying; Jun Zhu; Shengjie Yang; Meilan Yu
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.